Getinge AB ser. B (GETI-B) fair value: what the stock is really worth
As of Oct 19, 2026: fair value (intrinsic value) of Getinge AB ser. B stock SEK 184, price SEK 260, upside -29.4%, quality 62 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.
How to read this chart
60‑month range kr 157.34 – kr 388.80 · fair‑value band kr 120.07 – kr 270.74 · the kr 260.40 price screens above the kr 183.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 14, 2026.
Follow Getinge AB ser. B in your weekly email
Every Wednesday you see whether Getinge AB ser. B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments.
Show moreShow less
It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions.
In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions.
Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation.
Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium.
It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Stock analysis
Getinge AB ser. B (GETI-B) currently trades at kr 260.40, while our model-based Fair Value estimate is kr 183.86, 29.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of kr 204.06 per share, and 4 of the 22 models we run sit above the kr 260.40 price.
Bear case: the Earnings-Based group reads lowest at kr 49.40, and 18 of the 22 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 120.07 (bear) to kr 270.74 (bull), the price of kr 260.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Getinge AB ser. B reported revenue of 35.0B SEK in FY2025 versus 27.0B SEK in FY2021, a compound +6.6%/yr. Reported net income was 2.3B SEK in FY2025, compounding −6.6%/yr from FY2021.
Key figures
Market cap 70.9B SEK (≈ $7.2B) Mid · P/E ratio 24.7 · P/S ratio 2.07 · EPS (TTM) kr 9.84 · Dividend yield 1.8% · Net margin 7.8% · Return on equity 9.0% · Return on assets (EBIT) 7.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 48% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −29%, GETI-B screens richer than that median.
Fair Value models
Bearkr 120.07Fair Value kr 183.86Bullkr 270.74
Price kr 260.40 · Upside -29.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 4.09 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Start year 2020 (pandemic). Over 10 years: +1.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−3.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.3%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.3% vs 4.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +12.6% a year for the price and +2.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Getinge shows a moderate profile in medical devices backed by its core hospital and Life Science offerings, yet limited evidence of durable advantages and low ROE point to only average profitability.
Main risk: The leadership shift in the Life Science division risks disrupting ongoing execution in biopharma and research equipment and could slow growth in that unit.
Getinge is seeing its Life Science division head depart for an external role at the end of October, with an internal acting successor stepping in from November. That unit has driven recent focus on biopharma and research equipment alongside the core hospital offerings. Will the leadership shift disrupt ongoing execution in Life Science or prove seamless enough to sustain the broader growth trajectory our models currently view as overvalued?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside−29.4% · Below median
Profitability
Return on equity (12 months)9.0% · Above median
Return on assets4.0% · Above median
Net margin (12 months)7.8% · Above median
Operating margin (12 months)16.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.7% · Below median
Dividend yield (12 months)1.8% · Below median
Balance sheet
Debt / equity0.27× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)24.7× · Cheaper than median
P/B2.41× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)2.07× · Cheaper than median
Price / free cash flow26.9× · Pricier than median
EV/EBITDA12.8× · Cheaper than median
PEG1.33× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)9· sector 33
PAST (return on equity)36· sector 16
HEALTH (low debt)87· sector 98
DIVIDEND (yield)36· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Getinge AB ser. B Fair Value". https://www.fairvalue-calculator.com/stock/GETI-B
Frequently asked questions
Is Getinge AB ser. B (GETI-B) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of kr 183.86 versus a price of kr 260.40, about −29% upside (overvalued).
What is the fair value of GETI-B?
Our model-based fair value for Getinge AB ser. B is kr 183.86 (as of Oct 14, 2026), built from audited fundamentals. The current price: kr 260.40.
What is the quality score of GETI-B?
Getinge AB ser. B has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Getinge AB ser. B (GETI-B)?
Our model-based price target is the fair value of kr 183.86 (as of Oct 14, 2026) from 22 valuation models. Cautious scenario kr 120.07, optimistic scenario kr 270.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Getinge AB ser. B stock forecast for 2026?
Our models put fair value at kr 183.86, about −29% upside versus a price of kr 260.40 (overvalued). Cautious scenario kr 120.07, optimistic scenario kr 270.74. The calculation is refreshed regularly with new filings.
What is the revenue of Getinge AB ser. B (GETI-B)?
Getinge AB ser. B reported trailing-twelve-month revenue of about 34.2B SEK (latest available figure, as of Oct 14, 2026).
Does Getinge AB ser. B pay a dividend?
Getinge AB ser. B currently shows a dividend yield of 1.82% relative to its recent price (as of Oct 14, 2026).
What growth is priced into Getinge AB ser. B (GETI-B)?
For today's price to be fair in a discounted-cash-flow model, Getinge AB ser. B would have to grow free cash flow by +14.8 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.2 % per year. As of Oct 14, 2026.
What discount rate (WACC) does the fair value of GETI-B use?
Our models discount Getinge AB ser. B at 9.1 %: a base by market capitalisation (mid), damped by beta 0.83, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Getinge AB ser. B that is +14.8 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Getinge AB ser. B (GETI-B) delivered so far?
Over the past 5 years revenue at Getinge AB ser. B grew +3.2 % a year. The price currently implies +14.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Getinge AB ser. B (GETI-B) growing?
The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into Getinge AB ser. B (+14.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Getinge AB ser. B (GETI-B)?
The free-cash-flow yield on the price is 3.72 %: that much free cash flow Getinge AB ser. B produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Getinge AB ser. B (GETI-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Getinge AB ser. B it is kr 183.86 per share (as of Oct 14, 2026), against a price of kr 260.40. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Getinge AB ser. B stock overvalued or undervalued in 2026?
As of Oct 14, 2026, GETI-B trades above its calculated fair value: price kr 260.40, fair value kr 183.86, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GETI-B?
No. The price is what the market pays today (kr 260.40); the fair value is what the company's own numbers justify (kr 183.86). For Getinge AB ser. B the two are kr 76.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Getinge AB ser. B worth?
The market values Getinge AB ser. B at about 70.9B SEK (market capitalisation, as of Oct 14, 2026). Per share that is kr 260.40; our models calculate a fair value of kr 183.86 per share.
What do the bullish and bearish scenarios say about GETI-B?
Our models span a range for Getinge AB ser. B: cautious scenario kr 120.07, base kr 183.86, optimistic kr 270.74 per share (as of Oct 14, 2026, price kr 260.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GETI-B?
Getinge AB ser. B trades at a price-to-earnings ratio of 24.7 (as of Oct 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 183.86 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 23.1 (reported for FY2025: 31.4). Other multiples: PEG 1.3, P/B 2.4, P/S 2.1, EV/EBITDA 12.8.
What is the PEG ratio of GETI-B?
The PEG ratio of Getinge AB ser. B is 1.33 (P/E divided by earnings growth, as of Oct 14, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Getinge AB ser. B (GETI-B)?
Balance-sheet figures for Getinge AB ser. B (as of Oct 14, 2026): return on equity 9.0%, debt of 0.27 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is GETI-B from its 52-week high?
Getinge AB ser. B trades at kr 260.40, at its 52-week high of kr 261.60 and 48% above the low of kr 176.27 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 183.86 is for.
Which stocks are comparable to Getinge AB ser. B?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Getinge AB ser. B stock attractive at the current price?
The data as of Oct 14, 2026: price kr 260.40, calculated fair value kr 183.86 (−29%), Quality Score 62/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GETI-B calculated?
We run Getinge AB ser. B through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 183.86, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Getinge AB ser. B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Getinge AB ser. B (GETI-B)?
The closing price on Oct 19, 2026 was kr 260.40. Our model-based fair value is kr 183.86, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Getinge AB ser. B right now?
Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 120.07 to kr 270.74) leaves room in how you read the outcome.
Where does the earnings growth of Getinge AB ser. B (GETI-B) come from?
Earnings per share at Getinge AB ser. B grew +4.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +0.8 %, EBIT margin +2.4 %, tax rate +0.0 %, residual (interest, one-offs) +0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Getinge AB ser. B
How large is the market capitalisation of Getinge AB ser. B (GETI-B)?
The market capitalisation of Getinge AB ser. B is 70.9B SEK (≈ $7.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Getinge AB ser. B (GETI-B)?
The price-to-sales ratio of Getinge AB ser. B is 2.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Getinge AB ser. B (GETI-B)?
Earnings per share at Getinge AB ser. B are kr 9.84 (price ÷ EPS = P/E 24.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Getinge AB ser. B (GETI-B)?
The dividend yield of Getinge AB ser. B is 1.8% (payout 35.4%, on adjusted earnings, reported 48.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Getinge AB ser. B (GETI-B)?
The net margin of Getinge AB ser. B is 7.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Getinge AB ser. B (GETI-B)?
The return on equity (ROE) of Getinge AB ser. B is 9.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Getinge AB ser. B (GETI-B)?
On an EBIT basis the return on assets of Getinge AB ser. B is 7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Getinge AB ser. B (GETI-B)?
The operating margin of Getinge AB ser. B is 16.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Getinge AB ser. B (GETI-B)?
Revenue at Getinge AB ser. B is growing +1.7% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Getinge AB ser. B (GETI-B)?
Earnings per share at Getinge AB ser. B are growing +60.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Getinge AB ser. B (GETI-B) carry?
The net debt of Getinge AB ser. B is 7.5B SEK (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Getinge AB ser. B in the live analysis
One click puts Getinge AB ser. B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 14, 2026